Paper
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
Published May 15, 2006 · I. Raad, R. Hachem, R. Herbrecht
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
314
Citations
11
Influential Citations
Abstract
BACKGROUND Conventional amphotericin B-based antifungal therapy for invasive fusariosis in patients with a hematologic malignancy results in a > or = 70% failure rate. Posaconazole is a broad-spectrum antifungal agent with in vitro and in vivo activity against Fusarium species. METHODS In this retrospective analysis of patients from 3 open-label clinical trials, we evaluated posaconazole for the treatment of invasive fusariosis. Twenty-one patients with proven or probable invasive fusariosis who had disease refractory to or who were intolerant of standard antifungal therapy received oral posaconazole suspension (800 mg per day in divided doses) as salvage therapy. RESULTS Successful outcome occurred in 10 (48%) of all 21 patients. Among patients with leukemia who received posaconazole therapy for >3 days, the overall success rate was 50%; for patients who recovered from myelosuppression, the success rate was 67%, compared with 20% for those with persistent neutropenia. CONCLUSION These results suggest that posaconazole is useful for the treatment of invasive fusariosis.
Non-RCT
Rigorous Journal
Highly CitedPosaconazole shows potential as a salvage treatment for invasive fusariosis in patients with hematologic malignancies, with a success rate of 48% in this group.
Full text analysis coming soon...